# Dialysis Kinetics and Adequacy

## Overview

Dialysis adequacy quantifies the effectiveness of renal replacement therapy (RRT) in removing uremic toxins. The primary clearance marker is **urea**, measured as Kt/V (a dimensionless ratio) or URR (urea reduction ratio) in hemodialysis and as weekly Kt/V in peritoneal dialysis \[1\]. Understanding kinetic models, solute transport, and membrane characteristics is essential for optimizing dialysis prescriptions and predicting patient outcomes.

------------------------------------------------------------------------

## Key Clinical Pearl

**“Adequate dialysis is necessary but not sufficient for patient survival. A patient with spKt/V 1.4 still requires excellent fluid management, blood pressure control, vascular access preservation, and nutritional support. Dialysis adequacy is one pillar of a comprehensive dialysis care plan.”**

------------------------------------------------------------------------

## Part 1: Fundamental Concepts

### What is Kt/V?

**Definition:** Kt/V is a dimensionless number representing the fractional urea clearance per treatment.

- **K** = dialyzer urea clearance (mL/min)
- **t** = dialysis time (minutes)
- **V** = urea distribution volume (approximates total body water, ~60% of body weight in mL)

\$\$\text{Kt/V} = \frac{K \times t}{V}\$\$

**Example calculation:** - K = 300 mL/min (typical HD dialyzer) - t = 240 minutes (4 hours) - V = 40 L (for 70 kg male)

\$\$\text{Kt/V} = \frac{300 \times 240}{40,000} = \frac{72,000}{40,000} = 1.8\$\$

### Why Urea?

- **Urea** is the primary end-product of protein metabolism; accumulation causes uremia
- **Solute transport principle:** Solutes move from blood (high concentration) → dialysate (zero concentration) via diffusion (small solutes like urea) and convection (larger solutes via ultrafiltration)
- **Urea kinetics** predict removal of water-soluble uremic toxins; other uremic toxins (phosphate, middle molecules, protein-bound toxins) behave differently

### Single-Pool vs Equilibrated Kt/V

**Single-pool Kt/V (spKt/V):** - Measured directly from blood sample at dialysis end - Does NOT account for urea rebound (rebound occurs post-dialysis as intracellular urea equilibrates with plasma) - Overestimates true urea removal

**Equilibrated Kt/V (eKt/V):** - Accounts for urea rebound post-dialysis - More accurate predictor of outcomes - Calculated from spKt/V using correction factor (typically: eKt/V ≈ spKt/V − 0.05)

**Clinical target:** spKt/V ≥1.4 (equivalent to eKt/V ≥1.2).

------------------------------------------------------------------------

## Part 2: Hemodialysis Adequacy

### KDOQI 2015 Guidelines for Hemodialysis Adequacy \[1\]

**Target spKt/V:** ≥1.4 per HD session (thrice weekly)

**Target URR:** ≥65% (minimum), goal ≥70%

**Rationale:** HEMO compared higher with standard dialysis dose; increasing dose did not significantly reduce mortality. Adequacy targets should follow KDOQI and include clinical assessment, treatment delivery and residual kidney function.

### Urea Reduction Ratio (URR)

**Formula:** \$\$\text{URR} = \frac{\text{Pre-dialysis BUN} - \text{Post-dialysis BUN}}{\text{Pre-dialysis BUN}} \times 100\$\$

**Advantages:** - Simple to calculate; requires two blood samples (pre and post) - No need to know dialyzer specifications or treatment time

**Disadvantages:** - Does NOT account for ultrafiltration contribution to solute removal - Overestimates true urea removal (Kt/V is more accurate) - Interchangeable with Kt/V for outcome prediction (mathematically related)

**Interpretation:** - URR \>70% = excellent adequacy - URR 65–70% = adequate - URR \<65% = inadequate; increase Kt/V via longer treatment, faster blood flow, or higher dialyzer clearance

### Factors Affecting Kt/V in Hemodialysis

| Factor | Effect on Kt/V | Mechanism |
|----|----|----|
| **Longer treatment time** | ↑ Kt/V | Increased (t) in numerator |
| **Higher blood flow (Qb)** | ↑ Kt/V | Increased dialyzer clearance (K) |
| **Higher dialysate flow (Qd)** | ↑ Kt/V | Increased dialyzer clearance (K) |
| **Larger dialyzer (surface area)** | ↑ Kt/V | Increased clearance (K) |
| **Shorter interdialytic interval** | ↑ Kt/V | More frequent treatment |
| **Higher body weight (V)** | ↓ Kt/V | Larger urea distribution volume |
| **Recirculation** | ↓ Kt/V | Blood mixing; reduces effective clearance |
| **Access stenosis** | ↓ Kt/V | Reduces blood flow; lower Qb |

### Dialyzer Selection and Membrane Characteristics

**Membrane material:** - **Cellulose-based:** Older, cheap; high thrombogenicity; lower biocompatibility - **Synthetic (polysulfone, polyethersulfone, PMMA):** Better biocompatibility; less leukopenia; preferred

**Surface area classification:** - **Small dialyzers:** \<1.3 m² (rarely used now) - **Medium dialyzers:** 1.3–1.8 m² (standard) - **Large dialyzers:** \>1.8 m² (for high Kt/V requirements)

**Membrane permeability (transport classification):** - **Low-flux:** Only removes small solutes (urea, creatinine); limited ultrafiltration - **High-flux:** Removes small AND middle molecules; superior ultrafiltration capacity - **High-flux preferred** for better outcomes and faster fluid removal

### Recirculation and Vascular Access Monitoring

**Recirculation:** Mixture of newly filtered blood with already-dialyzed blood returning via access; reduces effective clearance.

**Calculation:** \$\$\text{Recirculation (\\)} = \frac{K\_{in} - K\_{out}}{K\_{in}} \times 100\$\$

Where Kᵢₙ, Kₒᵤₜ = potassium concentrations (surrogate for urea).

**Acceptable recirculation:** \<10% (indicates good vascular access integrity).

**Clinical implication:** Rising recirculation suggests **access stenosis** or **thrombosis**; refer for access evaluation (ultrasound, angiography).

------------------------------------------------------------------------

## Part 3: Peritoneal Dialysis Adequacy

### PD-Specific Measures of Adequacy

**Peritoneal Kt/V (weekly):**

\$\$\text{Weekly Kt/V} = \frac{\[\text{24h urine urea + 24h peritoneal dialysate urea clearance}\]}{\[\text{Plasma urea}\] \times \text{V}}\$\$

**Assessment:** Interpret total weekly Kt/V together with symptoms, volume control, nutrition, residual kidney function and the individualized PD prescription. Increasing a clearance number alone does not establish better survival.

**Residual kidney function heavily influences adequacy:** A patient with 10 mL/min residual renal function (RRF) needs less PD solute clearance than an anuric patient; if RRF high, total weekly Kt/V can be lower.

### Creatinine Clearance in PD

**24-hour peritoneal + renal creatinine clearance (normalized for BSA):**

Target: ≥60 L/week/1.73 m² total (peritoneal + renal)

**Interpretation:** - High peritoneal creatinine clearance = good peritoneal membrane function (allows higher daily solute removal) - Declining peritoneal clearance over time = normal (membrane fibrosis, gradual loss of function)

### Peritoneal Membrane Characteristics

**Peritoneal Equilibration Test (PET):** - Standardized 4-hour dwell test comparing plasma and dialysate creatinine concentrations - Classifies patients as high, high-average, low-average, or low transporters

**Clinical implications:** - **High transporter:** Rapid solute exchange but poor fluid removal (short dwells recommended); risk of fluid retention - **Low transporter:** Slow solute exchange; good fluid removal; longer dwells needed; risk of hyperglycemia if glucose overabsorption

### PD Prescription Optimization

**Parameters adjusted to meet Kt/V targets:** - **Number of exchanges per day:** 4–5 (continuous ambulatory) vs automated (8–10 overnight) - **Dwell time:** Shorter for high transporters, longer for low transporters - **Dialysate volume per exchange:** 1.5–2.5 L (higher volume = more clearance but more glucose absorption) - **Dialysate concentration:** Standard 1.5% glucose vs 2.5% or 4.25% (hypertonic) for aggressive fluid removal

------------------------------------------------------------------------

## Part 4: Ultrafiltration and Fluid Management

### Ultrafiltration (UF) Rate

**Definition:** Net fluid removal during dialysis; depends on transmembrane pressure gradient (hydrostatic - oncotic pressure).

**Calculation:** \$\$\text{UF Rate} = \frac{\text{Weight loss (kg)} \times 1000}{\text{Treatment time (min)}}\$\$

**Safe ultrafiltration rates:** - **HD:** \<13 mL/kg/hr (KDOQI target; higher rates = intradialytic hypotension, cramps) - **PD:** \<10 mL/kg/day (peritoneal route; slower rate)

### Dry Weight Assessment

**Dry weight:** Estimated post-dialysis weight at which patient has no longer cardiopulmonary edema and normal blood pressure.

**Clinical methods to assess:** 1. **Physical exam:** Assess lung crackles, JVD, peripheral edema 2. **Blood pressure trends:** If SBP dropping steadily, patient may be below dry weight 3. **Echocardiography:** LV filling assessed; normal systolic function suggests euvolemia 4. **Bioelectrical impedance analysis (BIA):** Measures total body water; can trend fluid status 5. **Intradialytic Weight Gain (IDWG):** Gain \>3.5% of dry weight between treatments = volume overload

### Dialysis Disequilibrium Syndrome (DDS)

**Definition:** Neurologic symptoms (headache, nausea, restlessness, seizures, coma) occurring during or shortly after dialysis, thought to result from rapid osmolar gradients between plasma and CSF \[2\].

**Pathophysiology:** - Rapid urea removal from blood → osmolar gradient → fluid shifts into brain - Cerebral edema develops; intracranial pressure rises - Risk highest in patients with very high pre-dialysis BUN (\>150 mg/dL)

**Prevention:** - Gradual initiation of dialysis (lower Kt/V first treatments) - Shorter, more frequent treatments initially - Slower blood flow (reduce rapid urea removal) - Avoid aggressive ultrafiltration in first month of dialysis

**Management if occurs:** - Stop dialysis immediately - Hypertonic saline or mannitol IV (osmotic therapy to reduce cerebral edema) - Prophylactic anticonvulsants if severe - Slower future dialysis prescriptions

------------------------------------------------------------------------

## Part 5: Vascular Access for Hemodialysis

### Access Types and Characteristics

| Access Type | Surgery | Maturation Time | Thrombosis Risk | Infection Risk | Longevity | Preferred |
|----|----|----|----|----|----|----|
| **Arteriovenous fistula (AVF)** | Autologous vein-to-artery | 6–12 weeks | Lowest (5%/yr) | Lowest (0.5%/yr) | Longest (\>10 yrs) | **Yes** |
| **Arteriovenous graft (AVG)** | Synthetic prosthetic | 2–4 weeks | Moderate (25%/yr) | Moderate (1–2%/yr) | Medium (3–5 yrs) | Second choice |
| **Central venous catheter (CVC)** | Percutaneous (Hickman, Groshong, tunneled) | Immediate | High (40%/yr) | High (3–5%/yr) | Short (\<1 yr) | Temporary only |

### AVF Placement and Maturation

**Timing of referral:** When eGFR falls to 15–20 mL/min or when anticipated RRT within 6 months.

**Preferred sites (in order):** 1. **Distal forearm (cephalic-radial fistula):** Best outcomes; lowest complication rates 2. **Proximal forearm (cephalic-brachial or brachial-basilic fistula):** Alternative if distal forearm inadequate 3. **Upper arm (brachial-axillary or brachial-cephalic):** Last resort; higher steal syndrome risk

**Maturation requirements:** - Adequate vein size (\>2.5 mm diameter) and artery size (\>1.5 mm) - Duplex ultrasound before surgery to assess vessel anatomy - Post-surgery monitoring with clinical exam (palpable thrill, audible bruit) - Repeat ultrasound if inadequate maturation at 6–8 weeks

### CVC Placement (Temporary/Tunneled Femoral or Internal Jugular)

**Indications:** - Emergency dialysis initiation (same-day start before AVF/AVG available) - Temporary access during AVF/AVG maturation - Failed AVF/AVG unable to undergo further surgery

**Complications:** - **Infection (catheter-related bloodstream infections, CRBSIs):** 1–3 per 1000 catheter-days; risk increases with duration - **Thrombosis:** Often requires thrombolysis or replacement - **Stenosis:** Central venous stenosis from intimal hyperplasia (femoral vein stenosis particularly common) - **Tunneled CVC fibrin sheath formation:** Can occlude lumen after weeks; requires stripping

**Maintenance:** - Lock solution (heparin or alteplase) to prevent clotting - Sterile dressing changes 2–3×/week - Avoid routine flushing (increases infection risk)

------------------------------------------------------------------------

## Part 6: Anticoagulation in Hemodialysis

### Rationale for Anticoagulation

Bloodstream and artificial membranes are thrombogenic; dialyzer thrombosis results in blood loss, reduced treatment efficacy, and access loss.

### Heparin (Standard)

**Mechanism:** Activates antithrombin III; prolongs PTT.

**Dosing:** - **Bolus:** 50–100 units/kg IV at start of treatment - **Infusion:** 1000–2000 units/hr during treatment (adjust based on ACT or PTT)

**Monitoring:** - Activated clotting time (ACT) target: 150–200 seconds - Platelet count baseline and periodic (HIT risk)

**Advantages:** Cheap, fast onset/offset, reversible.

**Disadvantages:** - **Heparin-induced thrombocytopenia (HIT):** 0.5–1% incidence; life-threatening if immune-mediated - Short half-life (30–60 min); repeated dosing needed - Hyperkalemia (impairs aldosterone synthesis)

### Low-Molecular-Weight Heparin (LMWH)

**Mechanism:** Preferential Factor Xa inhibition; longer half-life than UFH.

**Dosing:** 1 mg/kg IV bolus, then 0.5 mg/kg at 2 hours of treatment.

**Monitoring:** Anti-Xa activity (target 0.3–0.7 IU/mL).

**Advantages:** Less frequent dosing; lower HIT risk.

**Disadvantages:** Accumulates in renal failure; longer bleeding risk; cannot be reversed quickly.

### Regional Anticoagulation (Citrate)

**Mechanism:** Citrate chelates calcium; prevents coagulation in dialysis circuit only (calcium reinfused post-filter).

**Use cases:** - High bleeding risk (perioperative, GI bleed, severe thrombocytopenia) - HIT history or active HIT

**Monitoring:** Monitor for **citrate toxicity** (hypocalcemia, metabolic acidosis) if citrate accumulates (liver dysfunction, renal failure).

### No Anticoagulation (“Safe Heparin”)

**Indications:** - Acute bleeding (GI bleed, recent surgery) - Severe thrombocytopenia (\<50k)

**Technique:** Flush lines with saline frequently; accept higher clot risk.

------------------------------------------------------------------------

## Part 7: Dialysis Adequacy and Clinical Outcomes

### Mortality and Adequacy

**HEMO Study (2002) \[3\]:** 1,846 patients were randomized to standard or higher dialysis dose and low- or high-flux membranes. Mean delivered single-pool Kt/V was 1.32 versus 1.71.

**Findings:** Neither higher dialysis dose nor high-flux assignment significantly reduced overall mortality in the primary comparison. Exploratory subgroup findings do not redefine the overall result.

**ADEMEX Trial (2002) \[4\]:** Randomized PD patients to lower (Kt/V 1.4–1.6) vs higher (Kt/V 2.0–2.3) adequacy.

**Findings:** - No mortality difference between adequacy targets - Residual kidney function more important than dialysis adequacy for outcomes

### Residual Kidney Function (RKF)

**Critical finding:** Patients with preserved RKF (GFR \>3–4 mL/min) have significantly better outcomes than anuric patients, independent of dialysis adequacy.

**Implication:** Preserve RKF aggressively: - Avoid nephrotoxic agents (NSAIDs, aminoglycosides) - Maintain euvolemia - Use RAAS blockade (ACE-I/ARB if tolerated)

### Nutritional Status and Adequacy

**Protein-energy wasting (PEW):** Common complication of inadequate dialysis.

**Monitor:** - Serum albumin (target \>3.8 g/dL) - Prealbumin (shorter half-life; more sensitive) - Lean body mass (DXA or bioelectrical impedance) - Dietary protein intake (1.0–1.2 g/kg/day for HD; 1.2–1.3 g/kg for PD)

**Dialysis prescription impacts nutrition:** Increased Kt/V and better tolerances allow better nutritional intake.

------------------------------------------------------------------------

## Part 8: Key Warnings

### Warning 1: Kt/V Alone Does Not Ensure Adequate Dialysis

A patient with spKt/V 1.8 may still feel uremic if: - **Anemia undertreated:** Hgb \<10 g/dL (fatigue, dyspnea) - **Phosphate uncontrolled:** PO₄ \>5.5 mg/dL (itching, bone pain) - **Hypertension uncontrolled:** SBP \>150 mmHg (headache, cardiovascular stress) - **Nutritional status poor:** Albumin \<3.5 g/dL (wasting, infection risk) - **Residual kidney function lost:** Transition from anuric to slightly higher solute accumulation

**Clinical pearl:** “Adequacy” is multidimensional; Kt/V is one metric.

### Warning 2: High Ultrafiltration Rates Cause Hemodynamic Instability

Patients pushed to UF rates \>13 mL/kg/hr develop: - Intradialytic hypotension (SBP drop \>20 mmHg; confusion, syncope) - Muscle cramps (hypovolemia) - Poor access blood flow (vascular collapse)

**Solution:** Use longer treatment times, slower UF rates; accept smaller weight gains between treatments if needed.

### Warning 3: Dialysis Disequilibrium in First Treatments

New dialysis patients with BUN \>150 mg/dL at initiation at high risk of cerebral edema. Start with low Kt/V; increase gradually over 2–4 weeks.

### Warning 4: Recirculation May Indicate Imminent Access Failure

Rising recirculation from \<10% to \>15% suggests stenosis; untreated, leads to thrombosis and loss of access. Order urgent duplex ultrasound and angiography.

------------------------------------------------------------------------

## Related Resources

- ← Back to Dialysis & RRT Hub
- ← Back to Nephrology Hub
- Back to Medical Education Dashboard

------------------------------------------------------------------------

## References

\[1\] National Kidney Foundation. KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update. *Am J Kidney Dis*. 2015;66:884–930. [PubMed](https://pubmed.ncbi.nlm.nih.gov/26498416/)

\[2\] Bagshaw SM, George C, Bellomo R. A comparison of the RIFLE and AKIN criteria for acute kidney injury in critically ill patients. *Nephrol Dial Transplant*. 2008;23:1569–1574. [PubMed](https://pubmed.ncbi.nlm.nih.gov/18281319/)

\[3\] Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. *N Engl J Med*. 2002;347:2010–2019. [PubMed](https://pubmed.ncbi.nlm.nih.gov/12490682/)

\[4\] Paniagua R, Amato D, Vonesh E, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. *J Am Soc Nephrol*. 2002;13:1307–1320. [PubMed](https://pubmed.ncbi.nlm.nih.gov/11961019/)

\[5\] Lok CE, Huber TS, Lee T, et al. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update. *Am J Kidney Dis*. 2020. [PubMed PMID 32778223](https://pubmed.ncbi.nlm.nih.gov/32778223/)

------------------------------------------------------------------------

*Last updated: 2026-02-28* *Board-review quality curriculum for nephrology education.*


---

[Website version](https://urinenephrology.org/student-resources/dialysis/dialysis-kinetics-adequacy.html) · Markdown synchronized October 3, 2026.